- Compared with adults, children are more susceptible to infections.
- In paediatric patients with juvenile idiopathic arthritis (JIA), infections are the most commonly reported AEs linked to biologic (b)DMARDs.1
- bDMARDs are an effective treatment option for JIA.1
- Compared with adult patients with RA, paediatric patients with polyarticular-course JIA (pJIA) receiving abatacept had a numerically higher rate of infections.2
- Blood concentrations achieved with bDMARDs may vary greatly between individualpatients.
- It is not known whether the infection risk is linked to abatacept exposure in patients with pJIA following the approved IV or SC dosing regimen.
This study was funded by Bristol-Myers Squibb. Professional medical writing and editorial assistance was provided by Bu Reinen, PhD, at Caudex and was funded by Bristol-Myers Squibb.
The Annual European Congress of Rheumatology, June 13-16, 2018, Amsterdam, Netherlands
By Julie A Passarell